Humacyte (HUMA) just unveiled an announcement.
At Humacyte, Inc.’s 2024 Annual Meeting, stockholders elected six Class III directors and confirmed Pricewaterhouse Coopers LLP as the independent auditor. The elected directors will serve until the 2027 annual meeting, while two were reclassified to Class II to balance board membership. With a 58.8% quorum, the voting outcomes showed solid support for the board’s nominees and the auditor’s ratification, reflecting stockholder confidence in company governance and oversight.
See more insights into HUMA stock on TipRanks’ Stock Analysis page.
